ETHSX (Eaton Vance Ww H&S;A)
Net Asset Value: 9.33 1-Day Return: -0.03 (-0.32%) YTD Return as of 2/9/12:Up 5.07%

Classification: GL Health/Biotechnology   Objective: GL Health/Biotech   Open to New Investors: Yes

Lipper Rating

Total Return Consistent Return Preservation Tax Efficiency Expense

The Lipper Leader system ranks a fund in the following categories: Total Return; Consistent Return; Preservation; Tax Efficiency; and Expenses. Funds are rated in ascending order on a numeric scale of 1 to 5, with '1' representing funds with the lowest rating, and '5' representing the highest rated funds and funds that are Lipper Leaders. Click here for more detail.

NAV Chart | Growth of $10,000
Fund Chart
Find a Broker »

Total Returns (As of 2/09/2012)

More
 YTD1Yr3Yr5Yr10Yr
Fund 5.07 7.87 9.21 5.26 4.98
Classification 7.65 9.79 12.55 3.35 4.90
Index (S&P 500) 7.70 4.50 18.30 0.90 4.20
% Rank in Class (1-best,100=worst)8074781249

Fund Stats

More
Investment Objective:GL Health/Biotech
Net Assets ($Mil)667.00
Inception Date:7/26/85
Manager Name, TenureTeam Managed, NA
Expense Ratio: 1.96%
Sales Charge:
Load Type:
  
Front-End Load
5.75%
0.00%

Top 10 Holdings (As of 10/31/11)

More
Company NameSymbol% Net Assets
Novartis Ag Ord NOVN 7.59
Mitsubishi Tanabe Pharma Corp Ord NA 5.63
Roche Holding G Par ROG 5.38
Pfizer Inc Ord PFE 4.45
Allergan Inc Ord AGN 4.19
Bristol Myers Squibb Co Ord BMY 4.00
Merck & Co Inc Ord MRK 3.80
Wellpoint Inc Ord WLP 3.57
Sanofi Sa Ord SAN 3.49
Unitedhealth Group Inc Ord UNH 3.17
% of Total Holdings 45.27

View Overview for:

tools

Stock Screener

Portfolio Tracker

See More Tools
From the Magazine
Read More Read More Read More Read More

Also